tert-butyl [1-(1-methyl-1H-tetrazol-5-yl)-piperidin-4-yl]-carbamate | 1033844-93-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: tert-butyl [1-(1-methyl-1H-tetrazol-5-yl)-piperidin-4-yl]-carbamate
• 英文别名: tert-butyl[1-(1-methyl-1H-tetrazol-5-yl)-piperidin-4-yl]-carbamate；tert-butyl N-[1-(1-methyltetrazol-5-yl)piperidin-4-yl]carbamate
• CAS: 1033844-93-7
• 化学式: C₁₂H₂₂N₆O₂
• 分子量: 282.346
• InChiKey: ZFMYSGMEVSOALY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  85.2
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  tert-butyl [1-(1-methyl-1H-tetrazol-5-yl)-piperidin-4-yl]-carbamate 、 甲烷磺酸 在 异丙醇 作用下， 以 异丙醇 为溶剂， 反应 2.0h， 以to give 1-(1-methyl-1H-tetrazol-5-yl)-piperidin-4-amine methanesulphonic acid salt as a white powder (35.0 g)的产率得到1-(1-Methyl-1h-tetrazol-5-yl)-piperidin-4-amine methanesulphonic acid salt
  参考文献：
  名称：

  Nicotinamide derivatives

  摘要：

  本发明涉及公式（I）的化合物及其药学上可接受的盐和溶剂化物，其中取代基如本文所定义，包含该类化合物的组合物以及该类化合物在治疗哮喘等各种疾病和症状方面的用途。

  公开号：

  US07902373B2
• 作为产物：
  描述：

  5-chloro-1-methyl-1H-tetrazole 、 4-叔丁氧羰基氨基哌啶 在 三乙胺 作用下， 以 水 、 正丁醇 为溶剂， 反应 5.0h， 生成 tert-butyl [1-(1-methyl-1H-tetrazol-5-yl)-piperidin-4-yl]-carbamate
  参考文献：
  名称：

  Nicotinamide Derivatives

  摘要：

  本发明涉及公式（I）的化合物及其药用可接受的盐和溶剂化合物，其中取代基如本文所定义，包含这种化合物的组合物以及这种化合物用于治疗各种疾病和状况，如哮喘。

  公开号：

  US20080146569A1

文献信息

• QUINOLINE-3-CARBOXAMIDES AS H-PGDS INHIBITORS
  申请人：Astex Therapeutics Limited

  公开号：EP3390384B1

  公开（公告）日：2021-09-15
• CHEMICAL COMPOUNDS
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：US20210238162A1

  公开（公告）日：2021-08-05

  The present invention relates to compounds of Formula (XI): wherein R 1a , R 2a , R 3a , R 4a , R 5a , R 6a , and Aa are as defined herein, and pharmaceutically acceptable salts thereof. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) inhibitors and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
• [EN] QUINOLINE-3-CARBOXAMIDES AS H-PGDS INHIBITORS<br/>[FR] QUINOLÉINE-3-CARBOXAMIDES UTILISÉS COMME INHIBITEURS DE H-PGDS
  申请人：ASTEX THERAPEUTICS LTD

  公开号：WO2017103851A1

  公开（公告）日：2017-06-22

  The present invention relates to compounds of Formula (XI) wherein R1a, R2a, R3a, R4a, R5a, R6a, and Aa are as defined herein, and pharmaceutically acceptable salts thereof. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) inhibitors and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
• Nicotinamide Derivatives
  申请人：Blake Tanisha D.

  公开号：US20080146569A1

  公开（公告）日：2008-06-19

  The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are as defined herein, compositions containing such compounds and the uses of such compounds for the treatment of various diseases and conditions such as asthma.

  本发明涉及公式（I）的化合物及其药用可接受的盐和溶剂化合物，其中取代基如本文所定义，包含这种化合物的组合物以及这种化合物用于治疗各种疾病和状况，如哮喘。
• Nicotinamide derivatives
  申请人：Pfizer Inc

  公开号：US07902373B2

  公开（公告）日：2011-03-08

  The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are as defined herein, compositions containing such compounds and the uses of such compounds for the treatment of various diseases and conditions such as asthma.

  本发明涉及公式（I）的化合物及其药学上可接受的盐和溶剂化物，其中取代基如本文所定义，包含该类化合物的组合物以及该类化合物在治疗哮喘等各种疾病和症状方面的用途。